SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0000947871-21-000140
Filing Date
2021-02-09
Accepted
2021-02-08 21:54:07
Documents
3
Group Members
ORBIMED CAPITAL GP VII LLCORBIMED CAPITAL LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 ss191817_sc13da.htm SC 13D/A 110318
2 JOINT FILING AGREEMENT ss191817_ex9901.htm EX-99.1 5930
3 FORM OF LOCK-UP AGREEMENT ss191817_ex9903.htm EX-99.3 34124
  Complete submission text file 0000947871-21-000140.txt   152058
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

IRS No.: 133976876 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address 3027 TOWNSGATE ROAD SUITE 300 WESTLAKE VILLAGE CA 91361
Business Address 3027 TOWNSGATE ROAD SUITE 300 WESTLAKE VILLAGE CA 91361 805-418-5006
Arcutis Biotherapeutics, Inc. (Subject) CIK: 0001787306 (see all company filings)

IRS No.: 812974255 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91349 | Film No.: 21603711
SIC: 2834 Pharmaceutical Preparations